Product Categories
| Country: | China |
|---|---|
| Tel: | |
| Mobile: | +8613726739909 |
| E-mail: | pengguizi@cti-cert.com |
| QQ: | |
| Skype: | Chat Now! |
| Product Name | MF | CAS | Details |
|---|
| Osimertinib Impurity 05 | C23H20FN5O2 | 2213409-62-0 | Details |
| Crizotinib Impurity11 | C13H9Cl2FN2O3 | 877397-70-1 | Details |
| Ibubinib impurity 10 | C50H48N12O4 | ?2417548-76-4 | Details |
| Osimertinib Impurity 03 | C7H6FNO3 | 448-19-1 | Details |
| Tofacitinib Impurity 07 | C19H22N8 | 2504210-38-0 | Details |
| Crizotinib Impurity 13 | C13H11Cl2FN2O2 | 2509276-79-1 | Details |
| Crizotinib Impurity15 | C8H7Cl2FO | 877397-65-4 | Details |
| Atrasentan Impurity 14 | Details |
| Quisinostat Impurity7 | Details |
| Quisinostat Impurity5 | Details |
| Lapatinib Impurity 06 | C22H21ClN4O4S | 1268997-70-1 | Details |
| ethyl (2S,5R)-5-[(benzyloxy)amino]piperidine-2-carboxylate ethanedioate | C17H24N2O7 | 1416134-48-9 | Details |
| Palbociclib Impurity17 | Details |
| Baricitinib Impurity 1 | C15H15N7O2S | Details |
| Palbociclib Impurity10 | C23H38N6O4 | Details |
| Lapatinib Impurity 02 | C29H26ClFN4O4S | 1026818-86-9 | Details |
| Lapatinib Impurity 05 | C55H43Cl2F2N7O6S | 2172855-57-9 | Details |
| Tofacitinib Impurity 11 | C13 H19 N5 | 2097982-05-1 | Details |
| Trametinib Impurity 16 | C26H23FIN5O5 | 1383430-03-2 | Details |
| Trametinib Impurity 18 | Details |
| Osimertinib Impurity 14 | C56H66N14O4 | 2919324-18-6 | Details |
| Crizotinib Impurity06 | C23H24Cl2FN5O2 | 1428476-74-7 | Details |
| Atrasentan Impurity 17 | Details |
| Atrasentan Impurity 11 | Details |
| Atrasentan Impurity 28 | Details |
| Ibubinib impurity 05 | Details |
| Ibubinib impurity 09 | C30H35N7O3 | Details |
| Crizotinib Impurity 01 | C26H30Cl2FN5O3 | 877399-51-4 | Details |
| Lapatinib Impurity 04 | C29H27FN4O4S | 633370-23-7 | Details |
| Osimertinib Impurity11 | C27H31N7O2 | 1421373-99-0 | Details |
| Tofacitinib Impurity02 | C4H5N3O2 | 873-83-6 | Details |
| Tofacitinib Impurity 12 | C14H19N5O | 2227199-28-0 | Details |
| 2-(3-bromo-4,5-dimethoxyphenyl)ethan-1-aminehydrochloride | C10H14BrNO2.ClH | 92015-18-4 | Details |
| Dexpanthenol Impurity2 | C9H19NO4 | 81-13-0 | Details |
| Atrasentan Impurity 19 | Details |
| Quisinostat Impurity2 | Details |
| Trametinib Impurity 08 | Details |
| Quisinostat Impurity4 | Details |
| Trametinib Impurity 06 | Details |
| Atrasentan Impurity 20 | Details |
| Atrasentan Impurity 22 | Details |
| Crizotinib Impurity12 | C13H11Cl2FN2O | 877397-71-2 | Details |
| Lapatinib Impurity07 | C26H19ClFN3O3 | 320337-48-2 | Details |
| Dexpanthenol Impurity3 | C9H19NO4 | Details |
| Ibubinib impurity 11 | C27H31N7O2 | Details |
| 5-BROMOVERATRALDEHYDE | C9H9BrO3 | 6948-30-7 | Details |
| Methylene Blue | C16H20ClN3OS | 7220-79-3 | Details |
| Dexpanthenol Impurity1 | C6H10O3 | 599-04-2 | Details |
| Atrasentan Impurity 26 | C18H38N2O | 34066-46-1 | Details |
| Phosphorothioic acid, 0,0,0-triphenyl esters, tert-Bu derivs. | 192268-65-8 | Details |
| Trametinib Impurity 10 | Details |
| Atrasentan Impurity 13 | Details |
| Atrasentan Impurity 21 | Details |
| Trametinib Impurity 07 | Details |
| Quisinostat Impurity6 | Details |
| Crizotinib Impurity07 | C29H34ClFN8O | Details |
| Osimertinib Impurity 09 | Details |
| Trametinib Impurity 05 | C18H15FIN3O4 | 871700-24-2 | Details |
| Tofacitinib Impurity01 | C6H5N3O | 3680-71-5 | Details |
| Baricitinib Impurity 2 | Details |
| Osimertinib Impurity 12 | C28H33N7O3 | 1975982-94-5 | Details |
| Atrasentan Impurity16 | Details |
| Atrasentan Impurity 10 | Details |
| Dasatinib Impurity05 | C33H42ClN11O3S | Details |
| Tofacitinib Impurity 03 | C6H5N3O2 | 39929-79-8 | Details |
| Lapatinib Impurity03 | C29H27ClN4O4S | 231277-91-1 | Details |
| Tofacitinib Impurity 08 | C8H10N4 | 90953-01-8 | Details |
| Osimertinib Impurity 13 | C27H33N7O2 | 2227103-37-7 | Details |
| Osimertinib Impurity 07 | 2850389-35-2 | Details |
| (R)-(+)-Verapamilic Acid | C16H21NO4 | 38175-99-4 | Details |
| Trametinib Impurity 04 | Details |
| Atrasentan Impurity 24 | Details |
| Atrasentan Impurity 27 | Details |
| Quisinostat Impurity8 | Details |
| Crizotinib Impurity14 | C13H10BrCl2FN2O | 877399-00-3 | Details |
| Osimertinib Impurity04 | C22H24N6O | Details |
| Lapatinib Impurity 01 | C29H26ClFN4O4S | 1393112-45-2 | Details |
| METHYLENE BLUE | C16H20ClN3OS | 122965-43-9 | Details |
| Lapatinib Impurity 08 | C26H17ClFN3O3 | 231278-84-5 | Details |
| Ruxolitinib Impurity 07 | C17H18N6 | Details |
| Atrasentan Impurity06 | Details |
| Atrasentan Impurity 12 | Details |
| Atrasentan Impurity 23 | Details |
| Quisinostat Impurity3 | Details |
| Trametinib Impurity 01 | Details |
| Trans-5-(Benzyloxyamino)piperidine-2-carboxylic acid | C13H18N2O3 | 1501980-29-5 | Details |
| Palbociclib Impurity13 | Details |
| TRIPHENYL PHOSPHOROTHIONATE | C18H15O3PS | 597-82-0 | Details |
| Trametinib Impurity 14 | Details |
| Atrasentan Impurity15 | Details |
| Atrasentan Impurity 09 | Details |
| Atrasentan Impurity 18 | Details |
| Dasatinib Impurity06 | C22H26ClN7O2S | Details |
| Palbociclib Impurity16 | Details |
| Osimertinib Impurity02 | C13H10ClN3 | 2364486-23-5 | Details |
| Osimertinib Impurity01 | C4H4N2O2 | 51953-14-1 | Details |
| Atrasentan Impurity 02 | Details |
| Atrasentan Impurity 25 | Details |
| Quisinostat Impurity1 | Details |
| Ibubinib impurity 13 | C27H31N7O2 | Details |
| Product Total： Product Page： | ||||
| 1 2 3 4 5 | ||||